Clinical Research on Probiotics: The Interface between Science and Regulation
Author(s) -
Carmen Tamayo
Publication year - 2008
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/523332
Subject(s) - medicine , clinical trial , clinical study design , regulatory science , protocol (science) , affect (linguistics) , risk analysis (engineering) , population , research design , quality (philosophy) , clinical research , intensive care medicine , microbiology and biotechnology , alternative medicine , management science , environmental health , pathology , engineering , biology , social science , linguistics , philosophy , epistemology , sociology
Although there exists some evidence of the safety and efficacy of probiotics for treatment of disease, many of the clinical trials have lacked methodological quality, particularly with regard to protocol design, selection of population, and product characterization. Depending on the regulatory route, data need to be collected carefully to satisfy regulatory requirements in the United States and elsewhere. This article discusses how the regulations for probiotics affect clinical research. It also describes clinical trial design and issues that affect the design of trials for probiotics conducted to improve the scientific evidence for these products.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom